Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, et al.·2005·The Lancet Oncology